Cardio-oncology & other

Atorvastatin and Aortic Stiffness During Anthracycline-Based Chemotherapy: A Secondary Analysis of a Randomized Clinical Trial

JAMA CardiolPublished Secondary analysis of the STOP-CA randomised trial

Primary result · ≥1 SD increase (0.8 m per second) in PWVResult — go to the resultOdds ratio 0.05 95% CI 0.02–0.16

Authors' conclusion

Pretreatment with atorvastatin was associated with preservation of vascular function among patients with lymphoma undergoing anthracycline-based chemotherapy.

Study context

Population
Patients with newly diagnosed lymphoma scheduled for anthracycline-based chemotherapy, no clinical indication for a statin152 with paired pulse wave velocity (PWV) data
Participants
300 patients
Comparison
Atorvastatin vs placebo
  • Atorvastatinn = 150
  • Placebon = 150reference
Primary endpoint
≥1 SD increase in CMR-derived aortic arch pulse wave velocity (PWV) and ≥1 SD decrease in ascending aortic distensibility (AAD)
Follow-up
12 months
Methodological detailsdouble-blind, multicentre, 9 academic centres in the US and Canada, post hoc end points
  • Double-blind
  • Multicentre
  • 9 academic centres in the US and Canada
  • Post hoc end points

Primary result

≥1 SD increase (0.8 m per second) in PWV

Odds ratio

0.05

95% CI 0.02–0.16

P < 0.001

Events by treatment group

Atorvastatin vs Placebo
OR 0.05 (95% CI 0.02–0.16); P < 0.001

As reported in the abstract

Secondary outcomes

≥1 SD decrease (1.8 × 10-3 mm Hg-1) in AAD · 12 months

OutcomeMean LVEF decline (95% CI)P value
LVEF decline associated with ≥1 SD increase in PWV2.70% (−4.65% to −0.81%)P = 0.006
  • ≥1 SD decrease (1.8 × 10-3 mm Hg-1) in ascending aortic distensibility (AAD): 168 with paired aortic distensibility (AD) data

PWV values, baseline vs 12 months

Atorvastatin: remained similar, mean (SD) 6.5 (1.9) vs 6.5 (2.0) m per second
Placebo: increased, 5.7 (1.8) vs 6.8 (2.0) m per second

Original publication

Atorvastatin and Aortic Stiffness During Anthracycline-Based Chemotherapy: A Secondary Analysis of a Randomized Clinical Trial. JAMA Cardiol. Published 1 January 2026. doi:10.1001/jamacardio.2025.4548

Summarised from the published abstract; every number is checked against it

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.